Get the Stockscreener App
1.62
2.41%
-0.04
After Hours:
1.63
0.010
+0.62%
Chemomab Therapeutics Ltd Adr stock is traded at $1.62, with a volume of 28,949.
It is down -2.41% in the last 24 hours and down -2.99% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
See More
Previous Close:
$1.66
Open:
$1.67
24h Volume:
28,949
Relative Volume:
0.48
Market Cap:
$11.66M
Revenue:
-
Net Income/Loss:
$-9.04M
P/E Ratio:
-1.1053
EPS:
-1.4656
Net Cash Flow:
$-23.55M
1W Performance:
-11.48%
1M Performance:
-2.99%
6M Performance:
-40.66%
1Y Performance:
+18.25%
1-Day Range:
$1.614
$1.71
1-Week Range:
$1.614
$1.89
52-Week Range:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.62 | 11.95M | 0 | -9.04M | -23.55M | -1.4656 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-24 | Initiated | Maxim Group | Buy |
| May-06-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-19-23 | Resumed | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Chemomab Therapeutics (CMMB) flags going-concern risk and reliance on nebokitug - Stock Titan
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday - Defense World
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 4.5% – Time to Sell? - Defense World
Chemomab’s nebokitug shows disease-modifying potential in PSC trial - Investing.com
Chemomab’s nebokitug shows disease-modifying potential in PSC trial By Investing.com - Investing.com UK
Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World
Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Nasdaq
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - Yahoo Finance
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - Yahoo Finance
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - Yahoo Finance
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Finviz
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - Finviz
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Nasdaq
Chemomab Therapeutics Ltd Share Price ADR Each Representing 80 Ord Shares SPON - Hargreaves Lansdown
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com
Jeff Jones Analyst Performance at Oppenheimer - MarketBeat
KURA Stock Rises More Than 15% This Past Week: Here's Why - Yahoo Finance
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics to Present at October 2024 Investor Conferences By Investing.com - Investing.com
Entero Therapeutics (ENTO) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2026 - MarketBeat
Chemomab Therapeutics Ltd. Sponsored ADR Earnings and Revenue – NASDAQ:CMMB - TradingView — Track All Markets
symbol__ Stock Quote Price and Forecast - CNN
Psyence Biomedical (PBM) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
PMGC (ELAB) Short Interest & Short Float | Updated May 2026 - MarketBeat
GRI Bio (GRI) Short Interest & Short Float | Updated Apr 2026 $GRI - MarketBeat
Chemomab Therapeutics LtdADR (CMMB) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
What is the current Price Target and Forecast for Chemomab Therapeutics (CMMB) - Zacks Investment Research
IO Biotech (IOBT) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Chemomab Therapeutics (CMMB) 10K Form and SEC Filings 2026 - MarketBeat
HCW Biologics (HCWB) Short Interest & Short Float | Updated May 2026 - MarketBeat
Chemomab Therapeutics (CMMB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
What date does Chemomab Therapeutics's (CMMB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Technical Analysis - Chartmill
Chemomab Therapeutics (CMMB) Institutional Ownership 2026 - MarketBeat
CMMB: Chemomab Therapeutics LtdADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Chemomab Therapeutics Ltd. Sponsored ADR Financial Statements – NASDAQ:CMMB - TradingView
CMMBChemomab Therapeutics Ltd ADR Stock Price and Quote - Finviz
Chemomab Therapeutics (CMMB) Earnings Date and Reports 2026 - MarketBeat
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):